A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata, Jun-Ichi Osuga, Takeshi Fujiwara, Shoji Yamazaki, Naoko Tomitani, Hiroshi Kanegae. Circulation 2018
Times Cited: 62




List of shared articles



Times cited

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
0

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang,[...]. Circulation 2021
2

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
0

Are SGLT2 Inhibitors New Hypertension Drugs?
Kazuomi Kario, Keith C Ferdinand, Wanpen Vongpatanasin. Circulation 2021
0

Timely and individualized heart failure management: need for implementation into the new guidelines.
Amr Abdin, Johann Bauersachs, Norbert Frey, Ingrid Kindermann, Andreas Link, Nikolaus Marx, Mitja Lainscak, Jonathan Slawik, Christian Werner, Jan Wintrich,[...]. Clin Res Cardiol 2021
0

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou, John Barbetseas. Am J Hypertens 2020
5



Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
Michael Böhm, David Fitchett, Anne Pernille Ofstad, Martina Brueckmann, Stefan Kaspers, Jyothis T George, Isabella Zwiener, Bernard Zinman, Christoph Wanner, Nikolaus Marx,[...]. J Hypertens 2020
3

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution.
Karen C Tran, Swapnil Hiremath. Am J Hypertens 2020
0

The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.
Takayuki Furuki, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori. J Clin Hypertens (Greenwich) 2020
1

Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.
Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E Ochoa-Martinez, Yamely Mendez, Chelsea H Chang, Salim Surani. World J Diabetes 2019
6